TLR6
Basic information
Region (hg38): 4:38822897-38856817
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the TLR6 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 1 | |||||
missense | 35 | 41 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 0 | 0 | 35 | 4 | 3 |
Variants in TLR6
This is a list of pathogenic ClinVar variants found in the TLR6 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
4-38827147-T-C | not specified | Uncertain significance (May 25, 2022) | ||
4-38827166-G-A | not specified | Uncertain significance (Sep 29, 2023) | ||
4-38827234-T-C | not specified | Uncertain significance (Mar 01, 2023) | ||
4-38827252-T-C | not specified | Uncertain significance (Nov 09, 2021) | ||
4-38827348-C-G | not specified | Uncertain significance (Nov 15, 2021) | ||
4-38827350-C-G | not provided (-) | |||
4-38827433-C-G | not specified | Uncertain significance (Nov 18, 2022) | ||
4-38827444-T-C | not specified | Uncertain significance (Oct 05, 2023) | ||
4-38827472-C-A | not specified | Uncertain significance (Dec 11, 2023) | ||
4-38827522-T-C | not specified | Uncertain significance (Aug 08, 2022) | ||
4-38827543-G-T | not specified | Uncertain significance (May 27, 2022) | ||
4-38827564-T-C | not specified | Uncertain significance (Mar 24, 2023) | ||
4-38827583-T-A | not specified | Uncertain significance (Apr 12, 2023) | ||
4-38827597-C-T | not specified | Likely benign (Jan 18, 2022) | ||
4-38827615-T-G | not specified | Uncertain significance (May 15, 2023) | ||
4-38827699-C-A | Benign (Jul 04, 2018) | |||
4-38827708-A-G | not specified | Uncertain significance (Mar 07, 2023) | ||
4-38827743-CAT-C | Abnormality of neuronal migration | Benign (Oct 31, 2014) | ||
4-38827798-T-C | not specified | Uncertain significance (Oct 04, 2022) | ||
4-38827844-T-C | not specified | Uncertain significance (Dec 20, 2021) | ||
4-38827850-T-G | not specified | Likely benign (Feb 28, 2024) | ||
4-38828081-C-T | Benign (Jul 31, 2018) | |||
4-38828149-T-G | not provided (-) | |||
4-38828384-C-T | not specified | Uncertain significance (Dec 06, 2022) | ||
4-38828461-A-C | not specified | Uncertain significance (Nov 23, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
TLR6 | protein_coding | protein_coding | ENST00000436693 | 1 | 33103 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.0000225 | 0.980 | 125648 | 1 | 99 | 125748 | 0.000398 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.936 | 347 | 400 | 0.868 | 0.0000198 | 5313 |
Missense in Polyphen | 65 | 80.616 | 0.80629 | 1203 | ||
Synonymous | 0.516 | 149 | 157 | 0.948 | 0.00000852 | 1470 |
Loss of Function | 2.10 | 11 | 21.5 | 0.512 | 9.19e-7 | 335 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00173 | 0.00173 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000652 | 0.000653 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.000238 | 0.000237 |
Middle Eastern | 0.000652 | 0.000653 |
South Asian | 0.000524 | 0.000490 |
Other | 0.000327 | 0.000326 |
dbNSFP
Source:
- Function
- FUNCTION: Participates in the innate immune response to Gram- positive bacteria and fungi. Specifically recognizes diacylated and, to a lesser extent, triacylated lipopeptides (PubMed:20037584). In response to diacylated lipopeptides, forms the activation cluster TLR2:TLR6:CD14:CD36, this cluster triggers signaling from the cell surface and subsequently is targeted to the Golgi in a lipid-raft dependent pathway (PubMed:16880211). Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Recognizes mycoplasmal macrophage-activating lipopeptide-2kD (MALP-2), soluble tuberculosis factor (STF), phenol-soluble modulin (PSM) and B.burgdorferi outer surface protein A lipoprotein (OspA-L) cooperatively with TLR2 (PubMed:11441107). In complex with TLR4, promotes sterile inflammation in monocytes/macrophages in response to oxidized low-density lipoprotein (oxLDL) or amyloid-beta 42. In this context, the initial signal is provided by oxLDL- or amyloid- beta 42-binding to CD36. This event induces the formation of a heterodimer of TLR4 and TLR6, which is rapidly internalized and triggers inflammatory response, leading to the NF-kappa-B- dependent production of CXCL1, CXCL2 and CCL9 cytokines, via MYD88 signaling pathway, and CCL5 cytokine, via TICAM1 signaling pathway, as well as IL1B secretion (PubMed:11441107, PubMed:20037584). {ECO:0000269|PubMed:11441107, ECO:0000269|PubMed:16880211, ECO:0000269|PubMed:20037584}.;
- Pathway
- Phagosome - Homo sapiens (human);Chagas disease (American trypanosomiasis) - Homo sapiens (human);Toll-like receptor signaling pathway - Homo sapiens (human);Tuberculosis - Homo sapiens (human);Regulation of toll-like receptor signaling pathway;Toll-like Receptor Signaling;Simplified Depiction of MYD88 Distinct Input-Output Pathway;Toll-like Receptor Signaling Pathway;toll-like receptor pathway;Toll-Like Receptors Cascades;Innate Immune System;Immune System;Adaptive Immune System;Antigen processing-Cross presentation;Class I MHC mediated antigen processing & presentation;Regulation of TLR by endogenous ligand;ER-Phagosome pathway;Toll Like Receptor 4 (TLR4) Cascade;MyD88:Mal cascade initiated on plasma membrane;Toll Like Receptor TLR1:TLR2 Cascade;Toll Like Receptor TLR6:TLR2 Cascade;Toll Like Receptor 2 (TLR2) Cascade;Endogenous TLR signaling
(Consensus)
Recessive Scores
- pRec
- 0.243
Intolerance Scores
- loftool
- 0.596
- rvis_EVS
- 0.89
- rvis_percentile_EVS
- 89.29
Haploinsufficiency Scores
- pHI
- 0.102
- hipred
- N
- hipred_score
- 0.132
- ghis
- 0.460
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.180
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Tlr6
- Phenotype
- hematopoietic system phenotype; reproductive system phenotype; immune system phenotype;
Gene ontology
- Biological process
- microglial cell activation;cell activation;toll-like receptor signaling pathway;MyD88-dependent toll-like receptor signaling pathway;inflammatory response;immune response;signal transduction;activation of NF-kappaB-inducing kinase activity;positive regulation of gene expression;negative regulation of toll-like receptor 2 signaling pathway;toll-like receptor 6 signaling pathway;TRIF-dependent toll-like receptor signaling pathway;toll-like receptor TLR6:TLR2 signaling pathway;detection of diacyl bacterial lipopeptide;defense response to bacterium;positive regulation of macrophage activation;positive regulation of I-kappaB kinase/NF-kappaB signaling;positive regulation of JUN kinase activity;innate immune response;positive regulation of interleukin-6 biosynthetic process;positive regulation of nitric oxide biosynthetic process;nitric oxide metabolic process;interleukin-1 beta secretion;positive regulation of NF-kappaB transcription factor activity;cellular response to diacyl bacterial lipopeptide;cellular response to oxidised low-density lipoprotein particle stimulus;positive regulation of cytokine production involved in inflammatory response;positive regulation of NLRP3 inflammasome complex assembly;positive regulation of oxidative stress-induced neuron death;positive regulation of reactive oxygen species biosynthetic process;cellular response to amyloid-beta;negative regulation of interleukin-8 secretion
- Cellular component
- Golgi apparatus;plasma membrane;integral component of plasma membrane;phagocytic vesicle membrane;Toll-like receptor 2-Toll-like receptor 6 protein complex;receptor complex;membrane raft
- Molecular function
- amyloid-beta binding;transmembrane signaling receptor activity;signaling receptor binding;protein binding;Toll-like receptor 2 binding;signaling receptor activity;identical protein binding;protein heterodimerization activity;lipopeptide binding